Parthenon Capital Announces Partnership Transaction With Trinity Partners


BOSTON, MA — Parthenon Capital Partners (“Parthenon”), a growth-oriented private equity firm, announced an investment in Trinity Partners, LLC (“Trinity” or the “Company”), a leading commercialization strategy and analytics firm that partners with life sciences companies to help bring innovative treatments to market. The current Trinity management team will continue to lead the organization post-closing.

“We are excited to partner with Parthenon to pursue our growth strategy of building a comprehensive commercialization services company. We will continue to support our clients by offering strategic insights, deep therapeutic expertise and analytical tools that create evidence-based solutions to optimize market access, product adoption and overall value,” said David Fitzhenry, Managing Partner and Chief Executive Officer at Trinity. “We believe Parthenon’s extensive investment experience in healthcare combined with their track record of supporting growth-oriented companies on a path to market leadership makes them the ideal partner as we expand our platform.”  Leslie Sandberg Orne, Senior Partner at Trinity also remarked, “Parthenon’s approach to growth resonated with us as we seek to extend our offering both organically and through strategic acquisitions. We see tremendous potential to build upon our relationship as a trusted partner to clients, while also bringing additional capabilities and innovative solutions to bear as they navigate an ever-evolving commercial landscape.”

Dave Ament, Co-CEO and Managing Partner at Parthenon said, “We are excited for this opportunity to partner with Dave, Leslie and the broader Trinity management team.  The Company has one of the most talented teams in the industry, and we believe Trinity is well-positioned as a platform to help support life sciences companies and bring innovative solutions to the industry.”

Kurt Brumme, a Principal at Parthenon added “Trinity has sustained a market-leading reputation over 20+ years of helping clients optimize the performance of their products against a backdrop of increasing competition and market access challenges. We are excited to build upon this track record of success and to support the Company as it further expands its capabilities across the full spectrum of commercialization services.”

Terms of the investment were not disclosed. Baird acted as exclusive financial advisor to Trinity in connection with the transaction.

Trinity Partners is a trusted life sciences strategy consulting firm that takes a personalized approach to working with pharmaceutical, biotech, medical device, and diagnostic clients worldwide to create evidence-based solutions that drive business strategy and impact bottom lines.  Visit to learn more.

Parthenon Capital Partners ( is a leading growth-oriented private equity firm based in Boston and San Francisco. Parthenon utilizes niche industry expertise and a deep execution team to invest in growth companies in technology and tech-enabled services industries. Parthenon seeks to be an active and aligned partner to management, either through recapitalization transactions or by backing strong executive teams. Parthenon focuses on healthcare services and financial services with a particular expertise in HCIT, payments and financial technology.